# Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease

> **NCT04277247** · PHASE2,PHASE3 · UNKNOWN · sponsor: **University of Calgary** · enrollment: 40 (estimated)

## Conditions studied

- Dystonia Disorder
- Parkinson Disease

## Interventions

- **DRUG:** Botulinum toxin type A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04277247
- **Lead sponsor:** University of Calgary
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-12
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-05-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04277247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04277247, "Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04277247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*